ArticleTranslational cancer research2025
Diagnostic value of a lactylation-related gene signature in hepatocellular carcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting lactylation in hepatocellular carcinoma: Mechanistic insights and therapeutic opportunities (Review).International journal of molecular medicine · 2026Review
- Development and validation of a GP73-based predictive model for the diagnosis of early-stage hepatocellular carcinoma.Journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The occurrence rate of liver cancer is increasing in recent years. The significance of lactylation in tumor cells should not be neglected. This study aimed to discover a gene signature related to lactylation that can be used for diagnostic applications. Methods: Data were downloaded from The Cancer Genome Atlas (TCGA), GSE14520, GSE84402, and GSE62232 datasets. Differential analysis and random forest analysis were performed in hepatocellular carcinoma (HCC). Receiver operating characteristic (ROC) curve was used to evaluate diagnostic efficiency, and logistic regression was established to obtain the risk score equation. Besides, the expression of genes in the signature was identified by TCGA database and verified by real-time quantitative polymerase chain reaction (RT-PCR). In order to analyze prognostic performance, patients diagnosed with HCC were stratified into either high risk score or low risk score categories based on the median risk score. In addition, immunotherapy and drug sensitivity of high risk score and low risk score groups were assessed. Results: The prognostic performance of the diagnostic model was validated in the Gene Expression Omnibus (GEO) dataset. The patients with high risk score had worse outcomes than those with low risk score in the TCGA database. ROC curves showed the characteristics of lactylation-related gene signature with a good predictive capability. Furthermore, we developed a predictive nomogram for HCC patients, utilizing the data resources from TCGA. Finally, in terms of assessing the potency of immunotherapy in patients, the low risk score group had a lower Tumor Immune Dysfunction and Exclusion (TIDE) score, indicating a good response to immunotherapy. Conclusions: Our identification of a gene model associated with lactylation presents a promising avenue for the development of targeted immunotherapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.